Alterity Therapeutics (ATHE) Research & Development (2013 - 2025)

Alterity Therapeutics has reported Research & Development for 10 years, with the latest figure at -$9.5 million in Q4 2025.

• On a quarterly basis, Research & Development fell 39.81% year-over-year to -$9.5 million in Q4 2025; TTM through Dec 2025 was -$33.8 million, a 1.46% decrease from a year earlier, with the FY2026 full-year figure at -$12505.6 billion, down 35.56% from the prior year.
• Research & Development was -$9.5 million for Q4 2025 at Alterity Therapeutics, down from -$6.8 million in the prior quarter.
• The five-year high for Research & Development was -$6.8 million in Q4 2024, with the low at -$9.5 million in Q4 2025.
• Average Research & Development over 5 years is -$8.6 million, with a median of -$9.0 million recorded in 2021.
• The sharpest annual moves came in 2024 and 2025: Research & Development gained 18.23% in 2024, then sank 39.81% in 2025.
• Over 5 years, Research & Development stood at -$9.0 million in 2021, then dropped by 2.99% to -$9.3 million in 2022, then grew by 10.48% to -$8.3 million in 2023, then gained by 18.23% to -$6.8 million in 2024, then plunged by 39.81% to -$9.5 million in 2025.
• The last three Research & Development figures came in at -$9.5 million (Q4 2025), -$6.8 million (Q4 2024), and -$8.3 million (Q4 2023), per Business Quant data.